Aiding the regression of neoplastic disease with 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole

US4584305A · kind A · utility

Assignee

• Janssen Pharmaceutica NA · BE

Inventors

• Josephus Brugmans · Schilde, BE
• William Pollack · Pittsburgh, US
• Paul Adriaan Jan Janssen · Vosselaar, BE
• Daniel Tripodi · Lebanon, US

Key dates

• Filing date: Feb 2, 1981
• Grant date: Apr 22, 1986
• Expiry date: Feb 2, 2001

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/425
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Process of aiding regression and palliation of neoplastic disease in animal and human hosts comprising systemic administration to phenylimidazo[2,1-b]thiazole or a nontoxic acid addition salt thereof. Preferably the active ingredient is administered in a sufficient amount to provide dosages over the range from about 1 mg to about 5 mg/kg of body weight of the host.